Telemedicine controlled‑substance rules
A clinician overview reports that the DEA and HHS have extended 2026 telemedicine flexibilities for prescribing controlled substances through the end of the year, while permanent policy remains unsettled. The piece focuses on practical implications for prescribers but notes broader regulatory uncertainty. (yoonhangkim.com)
A federal temporary rule lets clinicians keep prescribing controlled medications by telemedicine without a prior in-person visit through December 31, 2026. (federalregister.gov) The Drug Enforcement Administration and the Department of Health and Human Services said the extension took effect January 1, 2026, and preserves the same flexibilities used during the COVID-19 public health emergency. The agencies announced it on December 31, 2025, and the Department of Health and Human Services posted clinician guidance on January 2, 2026. (dea.gov) In plain terms, a doctor or other authorized prescriber can evaluate a patient by telemedicine and issue a controlled-substance prescription under the temporary rule if other federal and state requirements are met. The Department of Health and Human Services says the “full set” of pandemic-era prescribing flexibilities remains in place through the end of 2026. (hhs.gov) The baseline law is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which generally requires an in-person medical evaluation before a controlled-substance prescription. Congress wrote exceptions into that law, and the pandemic emergency triggered a broad telemedicine pathway that federal regulators have now extended four times. (federalregister.gov) The current extension keeps access stable for patients already getting attention-deficit hyperactivity disorder stimulants, anxiety medicines, sleep medicines, opioid-use-disorder treatment, and other scheduled drugs through remote care. It also delays the moment when prescribers would have to switch to a narrower permanent system. (hhs.gov) That permanent system is still unsettled. On January 17, 2025, the Drug Enforcement Administration published a proposed “special registration” framework for telemedicine prescribing and a separate final rule to expand buprenorphine treatment by telemedicine encounter. (federalregister.gov) The proposed framework would create three kinds of special registrations and add tighter recordkeeping, reporting, and prescription rules for some remote controlled-substance prescribing. The Drug Enforcement Administration said those changes were meant to expand access while reducing diversion, the term regulators use for drugs moving outside lawful medical channels. (dea.gov) Federal officials have been trying to replace the emergency rules since 2023. The Drug Enforcement Administration said it received more than 38,000 comments on earlier telemedicine proposals and held two days of public listening sessions before moving to another temporary extension for 2025. (dea.gov) The telemedicine rule for controlled substances is separate from Medicare’s broader telehealth payment rules. The Department of Health and Human Services says Medicare telehealth services can continue through December 31, 2027, even as the prescribing rules for scheduled drugs remain on a year-by-year extension. (hhs.gov) For clinicians, the practical date is December 31, 2026. Unless federal agencies finalize a permanent rule before then, the same temporary prescribing framework expires again at the end of that day. (federalregister.gov)
